| Document |
Document Title |
|
WO/2003/092706A1 |
The present invention relates to the use of xanthan gum as re-epithelializing agent and, in particular, to a pharmaceutical formulation comprising xanthan gum as a re-epitheliazing active principle eventually mixed with hyaluronic acid. ...
|
|
WO/2003/063859A1 |
The present invention relates to the pharmaceutical use of selective estrogen receptor modulators (SERMs) alone or in combination with progestins for the treatment or prevention of diseases associated with elevated cartilage degradation....
|
|
WO/2003/059931A1 |
The invention relates to a process for the preparation of 7&agr −methyl hydroxy steroids of the Formula I: (Formula I)&semi wherein R1 is hydrogen, methyl or C≡CH&semi R2 is (CH2)nOH, wherein n is 0, 1 or 2&semi by a copper mediated ...
|
|
WO/2003/051904A1 |
A process for producing a 21−hydroxypregnane derivative represented by the general formula (III), (III) characterized by protecting the 7−position hydroxy group of a compound represented by the formula (I) (I) and subsequently elimin...
|
|
WO/2003/048181A1 |
A compound of formula (I): wherein R1 represents hydrogen, chlorine, fluorine, hydroxy or acyloxy OC(O)X, wherein X may be a linear or branched C1-6 alkyl, C3-7 cycloalky, or aryl; R2 represents C3-8 cycloalkyl or C3-8 cycloalkenyl eithe...
|
|
WO/2003/047329A2 |
A method for producing a 6a-fluorinated corticosteroid or derivative thereof by reacting a17-hydroxy-21-ester epoxide of Formula (II) with a stereoselective fluorinating agent to stereoselectively form a 21-ester-17-hydroxy 6a-fluorinate...
|
|
WO/2003/018027A1 |
The present invention relates to the use of pregnanes in inducing analgesia, preferably without overt sedation, in a mammal in response to neuropathic pain, and compositions and kits therefore.
|
|
WO/2003/015791A1 |
3-Hydroxy-7-hydroxy steroids and 3-oxo-7-hydroxy steroids, especially the 7ß-isomers thereof, and pharmaceutically acceptable esters thereof are useful for protection against ischaemia-induced damage to peripheral organs, such as the he...
|
|
WO/2003/015793A1 |
The invention relates to the controlled release of preparations of therapeutic agents, for example a steroid; formulations comprising said preparations; and the use of said formulations to treat diseases such as those diseases which woul...
|
|
WO/2003/014141A1 |
17$g(a),21-Dihydroxypregna-4,9-diene-3,20-dione and 17$g(a),21-dihydroxypregna-4-ene-3,20-dione 17 and/or 21 esters of having remarkable antiandrogenic activity, and the processes for the preparation thereof.
|
|
WO/2003/010181A1 |
The invention relates to 6$g(a)-fluoropregnanes (I), wherein: the line of points between positions 1 and 2 represents a single or double bond; R¿1? denotes OH, OCOR¿2?, X, SO¿3?R¿3? or a (R¿7?)(R¿8?)(R¿9?)SiO-group, wherein X is h...
|
|
WO/2003/000696A1 |
The present invention relates to pharmaceutical compositions and methods using such compositions for the treatment of inflammatory disease. Such compositions contain a catalyst for the dismutation of superoxide, including superoxide dism...
|
|
WO/2002/102827A1 |
The present invention is a novel process for the transformation of 11$g(b), 17$g(a) dihydroxy-6$g(a)-methylpregna-1,4-diene-3,20-dione 17-acetate (III), to 11$g(b), 17$g(a),21-trihydroxy-6$g(a)-methylpregna-1,4-diene-3,20-dio
ne 21-aceta...
|
|
WO/2002/102826A1 |
The present invention is a novel process for the transformation of 17$g(a)-hydroxy-6$g(a)-methylpregn-4-ene-3,20-dione 17-acetate (Formula (I)) to 11$g(b),17$g(a),21-trihydroxy-6$g(a)-methylpregna-1,4-diene-
3,20-dione 21-acetate (Formul...
|
|
WO/2002/100437A2 |
Ophthalmic compositions comprising an ophthalmic drug, e.g. ketotifen, and a linear polysaccharide compound, e.g. a hyaluronic acid compound, are useful for topical once-a-day administration to the eye.
|
|
WO/2002/100878A1 |
A process for preparing flumethasone (6a,9a-diffluoro-11$g(b),17a,21-trihydroxy-16a-methyl-pregna
-1,4-diene-3,20-dione), fulmethasone 21-acetate or its 17-carboxyl androsten analogue which process comprises reacting a compound of formul...
|
|
WO/2002/094758A1 |
The present invention provides methods of making 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivatives according to the following general reaction scheme. The invention also provides intermediates useful in making such 21-[4'-(nitro...
|
|
WO/2002/089814A1 |
17-Methylene-androstan-3α-ol analogs are useful as corticotropin releasing hormone (CRH) inhibitors, and especially as anti-depressants, when administered to the vomeronasal organ. An improved synthesis of 17-methyleneandrost-4-en-3α-o...
|
|
WO2002041925B1 |
A method of sterilising a pharmaceutical composition containing a suspension of a pharmaceutical comprises rapidly heating the pharmaceutical composition from ambient temperature to an elevated temperature, maintaining it at or above the...
|
|
WO/2002/058634A2 |
The present invention relates to analogs of estradiol, which, in their most preferred embodiment, act as locally active estrogens without significant systemic action. A series of 16$g(a)-carboxylic acid substituted steroids sand their es...
|
|
WO/2002/053577A2 |
The present invention relates to novel steroid derivatives that ace on the gamma-aminobutyric acid receptor-chloride ionophore (GR) complex as well as methods for making the same and their applications to induce anesthesia, in the treatm...
|
|
WO/2002/051385A1 |
The invention relates to solid dispersions of nitrate active principles in at least one polymer chosen from the group consisting of polyvinyl pyrrolidone, cellulose derivatives or polyethylene glycol, their production processes and pharm...
|
|
WO/2002/051422A1 |
Preventives and/or remedies for inflammatory airway diseases which contain as the active ingredient steroid derivatives represented by the following general formula (1): (1) wherein R represents hydrogen, halogeno, hydroxy or -OCOR?1¿ (...
|
|
WO2002007683B1 |
The present invention relates to a composition comprising a) at least one antimycotic agent and b) at least one film forming agent wherein component b) is a derivative of chitosan selected from hydroxyalkylchitosans and carboxyalkylchito...
|
|
WO/2002/036606A1 |
This invention is directed to a method for treating an inflammatory condition, treating haematological and other malignancies, causing immunosuppression, or preventing or treating transplant rejection in man or other animals which compri...
|
|
WO/2002/036106A2 |
The invention relates to novel medicament compositions based on anticholinergics and corticosteroids, a method for the production thereof and the use thereof for treating respiratory conditions.
|
|
WO/2002/024206A1 |
A unit dose formulation comprises less than 2.5 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid. Once daily administration of the unit dose formulation between midnight and 6 a.m. for the treatment of rhe...
|
|
WO/2002/020552A1 |
A process for the preparation of pregnane derivatives which comprises reacting a compound (I) with an alkali metal or an alkaline earth metal in the presence of ammonia or an amine to obtain a compound (II), protecting the hydroxyl group...
|
|
WO/2002/008243A1 |
The present invention relates inter alia to a novel oxidation process for the synthesis of a known intermediate, useful in the preparation of anti-inflammatory steroids, the known intermediate being of formula (I).
|
|
WO2001058919A9 |
Syntheses of steroids such as 3-hydroxy-7 alpha -methyl-21-[2'-methoxy-4'-(diethylaminomethyl)-phenoxy]-19-n
orpregna-1,3,5(10)triene citrate ("SR 16234") and analogs thereof are provided, wherein 21-hydroxy-19-norpregna-4-en-3-one serve...
|
|
WO/2001/098322A1 |
The present invention comprises the design, synthesis and development of a new class of chemotherapeutic agents for prophylactic and therapeutic treatments in a mammal, particularly a human, believed to be at risk of suffering from a hor...
|
|
WO/2001/096293A1 |
Provided are vitamin D derivatives which exhibit excellent physiologic activities suitable for drugs, particularly remedies for dermatoses such as psoriasis, and are lowered in the calcium increasing activity. The derivatives are represe...
|
|
WO/2001/087923A1 |
Synovial CRH functions in a paracrine manner to induce the nuclear transcription factor NURR1, which is abundantly expressed in the inflammatory cells of both rheumatoid arthritis and psoriatic arthritis synovium. This induction is suppr...
|
|
WO/2001/074840A2 |
The present invention relates, $i(inter alia), to compounds having the general formula (I) in which: R?1¿ is a member selected from the group consisting of -OCH¿3? -SCH¿3?, -N(CH¿3?)¿2?, -NHCH¿3?, -NC¿4?H¿8?, -NC¿5?H¿10?, -NC¿...
|
|
WO/2001/072293A2 |
The present invention features methods of inhibiting progestin activity in a cell or in a subject in need of such inhibition, and methods of treating or preventing progestin-dependent conditions in a subject in need of such treatment or ...
|
|
WO/2001/040253A2 |
The invention concerns a 3-methylene steroid derivative having general formula (1) wherein R?1¿ is H or together with R?3¿ forms a $g(b)-epoxide or R?1¿ is absent if there is a 5-10 or 4-5 double bond; R?2¿ is (C¿1?-C¿5?)alkyl or C...
|
|
WO/2001/022959A2 |
The present invention provides methods for treating inflammatory conditions, including but not limited to, inflammatory bowel disease (ulcerative colitis, Crohn's disease, and proctitis), other noninfectious, inflammatory conditions of t...
|
|
WO/2000/062735A2 |
The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumor...
|
|
WO/2000/063229A1 |
Novel steroid derivatives represented by general formula (I) or pharmacologically acceptable salts thereof, useful as anti-inflammatory agents wherein R¿1? is a corticosteroid bonded through an ester linkage formed from the alcoholic hy...
|
|
WO/2000/053619A1 |
The disclosed invention relates to the unexpected finding of steroids for use as androgens which are characterized by a configuration opposite to that of natural steroids, viz. 14$g(a), 17$g(b). These steroids according to the invention ...
|
|
WO/2000/034306A1 |
The invention is directed to a novel class of 17$g(b)-acyl-17$g(a)-propynyl steroids which exhibit potent antiprogestational activity.
|
|
WO/2000/029088A2 |
The present invention provides, in one aspect, a novel method for recovering an organic solute from a predominantly aqueous solution. In one embodiment, the solution is contacted with a dry, non-conditioned sorbent medium held by a suppo...
|
|
WO/2000/023460A1 |
The invention pertains to a process for the preparation of a high purity composition of (7$g(a),17$g(a))- 17-hydroxy- 7-methyl- 19-nor-17-pregn- 5(10)-en-20-yn-3-one. The process provides for a composition with less than 0.5 % of (7$g(a)...
|
|
WO/2000/021977A1 |
This invention provides 5$g(a)-pregnane-3$g(b), (20S), 21-triol, 20-O-$g(b)-glucuronide and 5$g(a)-pregnane-3$g(b),20R-diol, 20-O-$g(b)-glucuronide and pharmaceutically acceptalbe salts thereof which are useful as progestational agents.
|
|
WO/1999/046279A2 |
Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17$g(b)-hydroxy...
|
|
WO/1999/032127A1 |
Compositions of angiostatic agents for treating GLC1A glaucoma and methods for their use are disclosed.
|
|
WO1998020151A9 |
Disclosed is a method for the production of an adrenocorticoid steroid represented by general formula (I), wherein R1 and R3 may be H, alkyl, substituted alkyl, silyl, acyl, acyloxy or carbamoyl (and wherein R1 need not be the same as R3...
|
|
WO/1999/028336A1 |
16$g(a),17$g(a)-Dialkylated steroids are prepared by reacting a 16$g(a)-alkyl-17(20)-enyl-20-silyl ether with an alkylating agent and an enol silyl ether cleaving agent in a suitable solvent.
|
|
WO/1999/025359A1 |
The invention provides a process for the sterilization of a powdered form of a glucocorticosteroid, sterile glucocorticosteroids, sterile formulations containing glucocorticosteroids and use thereof in the treatment of an allergic and/or...
|
|
WO/1999/003503A1 |
Methods for treating ocular neovascularization using photodynamic therapy in combination with an angiostatic steroid are disclosed.
|
